{"contentid": 488425, "importid": NaN, "name": "Phase III trial could pave way for new COVID-19 vaccine in the UK", "introduction": "French vaccine specialist Valneva has kicked off a Phase III trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.", "content": "<p><span style=\"font-weight: 400;\">French vaccine specialist Valneva (EPA: VLA) has kicked off a Phase III trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.</span></p>\n<p><span style=\"font-weight: 400;\">The Cov-Compare study will pit VLA2001 against AstraZeneca&rsquo;s (LSE: AZN) approved coronavirus vaccine, Vaxzevria, evaluating comparative immunogenicity.</span></p>\n<p><span style=\"font-weight: 400;\">Approximately 4,000 participants in the UK will receive two doses of either vaccine in the trial, which is supported by the National Institute for Health Research (NIHR).</span></p>\n<h2><strong>Vaccine strategy</strong></h2>\n<p><span style=\"font-weight: 400;\">VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.</span></p>\n<p><span style=\"font-weight: 400;\">While Valneva&rsquo;s option is not yet approved by any regulator, is it seen as a potentially important option for the UK&rsquo;s vaccine strategy, as repeat booster vaccinations have been shown to work well with this type of technology.</span></p>\n<p><span style=\"font-weight: 400;\">As well as being potentially suitable for boosting immunity, Valneva believes the candidate could be used at a later stage for routine vaccination, including addressing new variants.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The UK government has already ordered 100 million doses, and holds an option for a further 90 million doses for supply between 2023 and 2025. If exercised, the total cost would be up to 1.4 billion euros ($1.7 billion).</span></p>\n<h2><strong>Domestic production</strong></h2>\n<p><span style=\"font-weight: 400;\">Valneva, which is targeting regulatory submissions in the fall, has said it believes the vaccine could make a contribution to the UK&rsquo;s vaccination program later in 2021 and in 2022.</span></p>\n<p><span style=\"font-weight: 400;\">In the context of global disputes over vaccine supplies, with the USA blocking vaccine exports and the EU threatening to do the same, the use of a Scottish site for manufacturing is an important part of the UK&rsquo;s work with Valneva.</span></p>\n<p><span style=\"font-weight: 400;\">The facility in West Lothian has already </span><a href=\"https://www.thepharmaletter.com/content/article/edit/id/~$n%2022%20news%206.docx\"><span style=\"font-weight: 400;\">started commercial production of VLA2001</span></a><span style=\"font-weight: 400;\">, with the capacity to supply up to 250 million vaccine doses to the UK and internationally by the end of 2021.</span></p>\n<p><span style=\"font-weight: 400;\">Commenting on the latest trial, chief investigator Adam Finn, of the University of Bristol, said: &ldquo;Following very encouraging safety and immune response results from our Phase I/II trial, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;We definitely need more vaccines to help us out of this pandemic and this one is a very promising candidate.&rdquo;</span></p>", "date": "2021-04-22 11:34:00", "meta_title": NaN, "meta_keywords": "vaccine, trial, Valneva, candidate, COVID-, Phase, doses, important, inactivated, adjuvanted, option, million, specialist, French, kicked, approved, pave", "meta_description": "French vaccine specialist Valneva (EPA: VLA) has kicked off a Phase III trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-22 11:25:39", "updated": "2021-04-22 12:19:27", "access": NaN, "url": "https://www.thepharmaletter.com/article/phase-iii-trial-could-pave-way-for-new-covid-19-vaccine-in-the-uk", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lab_biotech_research_vaccine_big.jpg", "image2id": "lab_biotech_research_vaccine_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "France, UK", "company_tag": "AstraZeneca, Valneva", "drug_tag": "Vaxzevria, VLA2001", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-22 11:34:00"}